---
title: "Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286463794.md"
description: "ZYCUBO ® has been given the green light by the FDA for treating Menkes disease in the US. Additionally, Cyprium Therapeutics, a Fortress subsidiary, finalized the transaction of its Rare Pediatric Disease Priority Review Voucher (PRV) for a whopping $205 million."
datetime: "2026-05-14T20:12:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286463794.md)
  - [en](https://longbridge.com/en/news/286463794.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286463794.md)
generator: "portal-rs"
---

# Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

ZYCUBO ® has been given the green light by the FDA for treating Menkes disease in the US. Additionally, Cyprium Therapeutics, a Fortress subsidiary, finalized the transaction of its Rare Pediatric Disease Priority Review Voucher (PRV) for a whopping $205 million.

### Related Stocks

- [FBIO.US](https://longbridge.com/en/quote/FBIO.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBIOP.US](https://longbridge.com/en/quote/FBIOP.US.md)

## Related News & Research

- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [FBIO: Q1 2026 net income soared to $108.4M, fueled by PRV sale and ZYCUBOⓇ approval](https://longbridge.com/en/news/295707458.md)
- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)
- [U.S. kindergarten vaccine coverage falls, CDC says](https://longbridge.com/en/news/296136711.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**